Cocrystal Pharma, Inc. (COCP) insider-linked trust purchases 75,000 shares
Rhea-AI Filing Summary
An entity associated with Cocrystal Pharma director and 10% owner Phillip Frost, M.D., Frost Gamma Investments Trust, purchased 75,000 shares of common stock on 2026-08-03 in an open-market or private transaction at a weighted average price of $0.9412 per share, with individual trade prices between $0.87 and $0.9499. Following this purchase, the trust holds 1,983,551 shares of Cocrystal Pharma common stock indirectly. Frost also has 27,100 shares held directly, which include shares issuable upon vesting of restricted stock units. Frost disclaims beneficial ownership of shares held by Frost Gamma Investments Trust and by OPKO Health, Inc., except to the extent of any pecuniary interest, and the transaction is not reported as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 75,000 shares
Net Buy
2 txns
Insider
FROST PHILLIP MD ET AL
Role
Director, 10% Owner
Bought
75,000 shs ($71K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F2 | 75,000 | $0.9412 | $71K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,983,551 shares (Indirect, By Frost Gamma Investments Trust);
Common Stock — 27,100 shares (Direct)
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.87 to $0.9499, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.
- F2. These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F3. Includes shares of common stock issuable upon vesting of restricted stock units.
Key Figures
Common stock purchased: 75,000 shares
Weighted average purchase price: $0.9412 per share
Trade price range: $0.87–$0.9499 per share
+2 more
5 metrics
Common stock purchased
75,000 shares
Shares of Cocrystal Pharma common stock purchased on 2026-08-03 by Frost Gamma Investments Trust
Weighted average purchase price
$0.9412 per share
Weighted average price for the 75,000-share purchase; trades ranged from $0.87 to $0.9499
Trade price range
$0.87–$0.9499 per share
Price range of individual transactions comprising the reported weighted average purchase price
Indirect holdings after purchase
1,983,551 shares
Cocrystal Pharma common shares held indirectly via Frost Gamma Investments Trust after the transaction
Direct holdings after transaction
27,100 shares
Common shares held directly by Phillip Frost, including shares issuable upon vesting of RSUs
Key Terms
weighted average price, restricted stock units, pecuniary interest, beneficial ownership
4 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock units financial
"Includes shares of common stock issuable upon vesting of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
pecuniary interest financial
"except to the extent of any pecuniary interest therein"
beneficial ownership financial
"disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider purchase in Cocrystal Pharma (COCP) stock did Phillip Frost report?
Phillip Frost reported that Frost Gamma Investments Trust purchased 75,000 COCP common shares on 2026-08-03 at a weighted average price of $0.9412 per share, with individual trades executed between $0.87 and $0.9499 in open-market or private transactions.
Does Phillip Frost have direct holdings in Cocrystal Pharma (COCP)?
Yes. In addition to indirect holdings through Frost Gamma Investments Trust, Phillip Frost directly holds 27,100 COCP shares. This direct position includes shares issuable upon vesting of restricted stock units, as noted in the footnotes to the Form 4 filing.
Was the reported COCP insider purchase made under a Rule 10b5-1 trading plan?
No. The Form 4’s Rule 10b5-1 checkbox is not marked as applicable, indicating the 75,000-share purchase of Cocrystal Pharma (COCP) common stock by Frost Gamma Investments Trust was not reported as executed under a Rule 10b5-1 trading plan.